Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1423142
This article is part of the Research Topic The complex phenotype of Diabetic Cardiomyopathy: clinical indicators and novel treatment targets View all 9 articles

Causal association between 1400 metabolites and Dilated cardiomyopathy: A bidirectional two-sample mendelian randomization analysis

Provisionally accepted
Xianghui Zeng Xianghui Zeng 1Qingfeng Zeng Qingfeng Zeng 1Xianggui Wang Xianggui Wang 2Kening Li Kening Li 2Jincheng Wu Jincheng Wu 2Jianping Luo Jianping Luo 2*
  • 1 Ganzhou Hospital of Traditional Chinese Medicine, Ganzhou, Jiangxi Province, China
  • 2 Ganzhou People's Hospital, Ganzhou, China

The final, formatted version of the article will be published soon.

    Background: Dilated cardiomyopathy (DCM) is a cardiac disease with a poor prognosis of unclear etiology. Previous studies have shown that metabolism is associated with DCM. This study investigates the causal relationship between 1400 metabolites and DCM using a two-sample Mendelian randomization (MR) approach.The study utilized data from the OpenGWAS database, comprising 355,381 Europeans, including 1,444 DCM cases. A total of 1,400 metabolites were evaluated for their causal association with DCM. Instrumental variables (IVs) were selected based on genetic variation and used in the MR analysis.The primary analysis method was inverse variance weighting (IVW), supplemented by weighted median-based estimation and sensitivity analyses.Of the 1,400 metabolites analyzed, 52 were identified as causally associated with DCM.The analysis revealed both positively and negatively correlated metabolites with DCM risk. Notable findings include the positive correlation of Tryptophan betaine and 5-methyluridine (ribothymidine) levels, and an inverse association of Myristoleate and Erythronate levels with DCM.The study provides significant insights into the metabolites potentially involved in the pathogenesis of DCM. These findings could pave the way for new therapeutic strategies and biomarker identification in DCM management.

    Keywords: dilated cardiomyopathy, Metabolites, Mendelian randomization, Causal analysis, genetic variants, Epidemiology

    Received: 25 Apr 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Zeng, Zeng, Wang, Li, Wu and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jianping Luo, Ganzhou People's Hospital, Ganzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.